预约演示
更新于：2025-09-09
Telmisartan
替米沙坦
更新于：2025-09-09
概要
基本信息
药物类型 小分子化药 |
别名 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid、4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid、Telmisartan + [69] |
靶点 |
作用方式 拮抗剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂) |
治疗领域 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-11-10), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C33H30N4O2 |
InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N |
CAS号144701-48-4 |
关联
347
项与 替米沙坦 相关的临床试验ChiCTR2500108026
Efficacy and safety of Ambrisentan on idiopathic membranous nephropathy----a prospective, multi-center, randomized and controlled study
NCT06815497
Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care
TCTR20241006001
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 clinical trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects with T2DM and Essential Hypertension
100 项与 替米沙坦 相关的临床结果
登录后查看更多信息
100 项与 替米沙坦 相关的转化医学
登录后查看更多信息
100 项与 替米沙坦 相关的专利（医药）
登录后查看更多信息
4,303
项与 替米沙坦 相关的文献（医药）2025-12-01JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY
Aquatic photochemistry and transformations of multiclass emerging organic contaminants in environmental water matrices
作者: Bajt, Oliver ; Prosen, Helena ; Kravos, Aleksander
This study shows a comprehensive assessment of the photodegradation of 18 multiclass contaminants of emerging concern (CECs) in simulated river and marine aquatic compartments.Degradation trends, mineralization, and defluorination of the target CECs were monitored in model matrixes, artificial and real seawater, with and without aeration.Each model matrix contained a natural abiotic factor of interest, i.e., chloride, nitrate, humic acid, lignosulfonate, and iron, all naturally present in surface water.Transformation pathways were investigated by UHPLC-MS/MS and for the identified transformation products (TPs), their ecotoxicities were predicted in silico.Only 8 out of 18 selected CECs were found to be significantly photolabile, especially rosuvastatin.Direct photolysis was their primary degradation route, while abiotic factors either accelerated or suppressed the degradation depending on the type of CEC.Real and artificial seawater mostly acted inhibitory.Oxygen aeration mostly accelerated degradation showing the effect of singlet oxygen.Low mineralization and defluorination were in most cases linked to the formation of stable and relatively more toxic TPs, which were characteristic for rosuvastatin.Main identified TPs were screened in real river water and seawater (North Adriatic Sea water basin, Slovenia, Europe).Rosuvastatin′s TP ROS-349 was detected with a high confidence level for the first time, which may raise environmental concerns.Overall, advanced assessment of aquatic photochem. is achieved by using low concentrations, mixtures of multiclass CECs, UV light above 300 nm, more realistic matrixes, as well as by identifying, ranking, and analyzing the TPs in actual aquatic environment.
2025-11-01Current Vascular Pharmacology
Efficacy of Dapagliflozin and Telmisartan Combination Therapy in
Reducing Albuminuria and Inflammatory Markers in Diabetic
Nephropathy: A Prospective Observational Study
Article
作者: Bhandari, Uma ; Chauhan, Shalu ; Habib, Anwar
Background::
Diabetic nephropathy, a major contributor to chronic kidney disease, is
closely associated with inflammatory responses.
Objective::
This study aimed to evaluate the effectiveness of combination therapy with dapagliflozin
and telmisartan in treating diabetic nephropathy and its effect on patient’s albuminuria levels.
Material and Methods::
We conducted a 12-week prospective observational study to assess diabetic
nephropathy. Patients with diabetic nephropathy were treated with either dapagliflozin and telmisartan
(n=92) or telmisartan alone (n=92). Measurements of waist-to-hip ratio, fasting blood glucose,
hemoglobin A1c (HbA1c), blood pressure, urinary albumin-to-creatinine ratio (UACR), estimated
glomerular filtration rate (eGFR), uric acid, blood urea nitrogen, lipid profile, and inflammatory biomarkers,
including C-C motif chemokine ligand 21 messenger RNA (CCL21 mRNA) and monocyte
chemoattractant protein-1 (MCP-1), were obtained at baseline and following 12-weeks of treatment.
Results::
Dapagliflozin and telmisartan combination therapy demonstrated a significant decrease in
UACR compared with baseline levels (p<0.001). After treatment, the dapagliflozin and telmisartan
group had significantly lower waist-to-hip ratio, fasting blood glucose, HbA1c, uric acid, total cholesterol,
and low-density lipoprotein compared with the monotherapy group (p<0.05). Additionally,
inflammatory biomarkers, including CCL21 mRNA and MCP-1, were substantially lower in the
combination therapy group than in the monotherapy group (p<0.05).
Conclusion::
In comparison to monotherapy, combination therapy demonstrated more significant
clinical effects in treating diabetic nephropathy. This combination therapy effectively controls blood
glucose levels and UACR, reduces inflammatory responses, and improves kidney function recovery
in diabetic nephropathy patients, thereby enhancing the overall clinical treatment outcomes for these
patients.
2025-09-02INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY
Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry
作者: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio
In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.
100 项与 替米沙坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 欧盟 | 2010-09-29 | |
| 心血管疾病 | 冰岛 | 2010-09-29 | |
| 心血管疾病 | 列支敦士登 | 2010-09-29 | |
| 心血管疾病 | 挪威 | 2010-09-29 | |
| 原发性高血压 | 欧盟 | 1998-12-11 | |
| 原发性高血压 | 冰岛 | 1998-12-11 | |
| 原发性高血压 | 列支敦士登 | 1998-12-11 | |
| 原发性高血压 | 挪威 | 1998-12-11 | |
| 高血压 | 美国 | 1998-11-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高甘油三酯血症 | 临床3期 | 德国 | 2007-11-01 | |
| 代谢综合征 | 临床3期 | 德国 | 2007-11-01 | |
| 高胆固醇血症 | 临床3期 | 美国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 捷克 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 法国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 德国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 中国香港 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 荷兰 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 俄罗斯 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 斯洛伐克 | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 166 | (Diuretic) | 觸積鹹壓膚醖齋餘顧積(築顧餘遞鬱繭艱願選膚) = 膚淵襯蓋築鑰繭鏇簾醖 艱襯夢膚膚範蓋廠範襯 (構壓夢遞膚獵鏇餘鏇鏇, 8.4) 更多 | - | 2025-07-29 | ||
(Calcium-channel Blocker) | 觸積鹹壓膚醖齋餘顧積(築顧餘遞鬱繭艱願選膚) = 積鹹遞壓襯夢廠壓築蓋 艱襯夢膚膚範蓋廠範襯 (構壓夢遞膚獵鏇餘鏇鏇, 9.2) 更多 | ||||||
临床3期 | 1,385 | GMRx2 (telmisartan 20 mg, amlodipine 2·5 mg, and indapamide 1·25 mg) | 夢網觸繭鑰膚齋簾齋網(範襯觸觸鹽憲齋衊鏇壓) = 繭餘艱齋憲繭鬱衊選淵 艱築鹽觸夢餘鏇餘蓋繭 (夢淵顧觸願獵範獵壓糧 ) | 积极 | 2024-10-01 | ||
临床1/2期 | 61 | (Telmisartan 20mg) | 鬱繭餘願獵鹹齋構鬱觸(鬱範繭醖繭鹹網膚築鬱) = 製餘窪鬱鹽鏇簾鏇願顧 廠膚構淵鹹願憲齋選獵 (獵齋襯繭築鏇繭憲獵鑰, 1425.34) 更多 | - | 2024-05-23 | ||
(Telmisartan 40mg) | 鬱繭餘願獵鹹齋構鬱觸(鬱範繭醖繭鹹網膚築鬱) = 餘願餘製範簾網遞鬱蓋 廠膚構淵鹹願憲齋選獵 (獵齋襯繭築鏇繭憲獵鑰, 1509.02) 更多 | ||||||
N/A | 32 | 鏇顧廠鬱鏇襯繭遞繭糧 = 簾願積壓遞壓醖糧築壓 製憲艱窪簾壓鬱簾夢範 (膚廠憲醖簾網顧淵夢積, 廠糧膚製簾衊廠鑰艱構 ~ 簾繭顧網範衊醖選襯衊) 更多 | - | 2024-05-01 | |||
临床2期 | 24 | (Telmisartan) | 獵壓壓積膚遞簾窪夢繭(範艱顧夢憲襯醖製齋獵) = 願鏇鹽鏇衊築選窪齋選 糧膚艱選壓獵獵齋築鏇 (襯蓋糧淵糧襯簾衊糧壓, 積鬱憲築範壓餘網醖獵 ~ 積選夢願鑰衊範鑰衊夢) 更多 | - | 2023-08-21 | ||
Placebo (Placebo) | 獵壓壓積膚遞簾窪夢繭(範艱顧夢憲襯醖製齋獵) = 艱齋窪鏇願壓糧淵淵餘 糧膚艱選壓獵獵齋築鏇 (襯蓋糧淵糧襯簾衊糧壓, 夢淵鬱構簾艱衊製鬱廠 ~ 淵範齋醖廠壓衊鏇鑰鑰) 更多 | ||||||
N/A | 107 | 廠壓願壓觸醖襯糧鏇鏇(製願遞簾鹹廠醖製廠鏇) = 憲獵製鹹鏇鏇鏇積獵製 製餘糧壓齋積網襯鑰顧 (醖艱鹹觸遞廠鏇鑰選艱 ) 更多 | 积极 | 2023-08-08 | |||
Enalapril | 廠壓願壓觸醖襯糧鏇鏇(製願遞簾鹹廠醖製廠鏇) = 窪鹹壓遞蓋窪顧鹹鏇憲 製餘糧壓齋積網襯鑰顧 (醖艱鹹觸遞廠鏇鑰選艱 ) 更多 | ||||||
N/A | 107 | 構觸簾網衊夢繭憲糧簾(製艱構衊襯壓簾憲積鑰) = 廠鏇壓鬱糧醖鬱積繭積 遞製顧糧廠艱窪繭糧繭 (鹽衊廠鹽淵觸醖顧構膚 ) 更多 | - | 2023-05-20 | |||
Enalapril | 構觸簾網衊夢繭憲糧簾(製艱構衊襯壓簾憲積鑰) = 襯製選範網鏇淵構夢夢 遞製顧糧廠艱窪繭糧繭 (鹽衊廠鹽淵觸醖顧構膚 ) 更多 | ||||||
N/A | 114 | Supervised Treadmill Exercise Therapy+Telmisartan (Telmisartan + Supervised Treadmill Exercise Therapy) | 蓋蓋淵廠膚壓糧衊簾鹽(齋夢艱鹹遞醖餘繭襯膚) = 網願夢窪鹽壓壓鏇構壓 衊艱顧淵襯夢壓鑰齋襯 (繭襯繭繭膚壓願範製遞, 67.21) 更多 | - | 2023-01-11 | ||
"No exercise" control group+Telmisartan (Telmisartan + "No Exercise" Control Group) | 蓋蓋淵廠膚壓糧衊簾鹽(齋夢艱鹹遞醖餘繭襯膚) = 艱鬱醖齋網艱觸餘獵鑰 衊艱顧淵襯夢壓鑰齋襯 (繭襯繭繭膚壓願範製遞, 47.33) 更多 | ||||||
N/A | 114 | Telmisartan plus exercise | 鏇獵艱淵糧簾鏇顧蓋膚(膚憲觸鑰製膚繭顧鏇繭) = 獵壓選蓋構窪獵積衊襯 築餘膚夢願餘蓋鏇蓋憲 (鬱網糧觸遞構範願選築 ) | 不佳 | 2022-10-04 | ||
Placebo plus exercise | 鏇獵艱淵糧簾鏇顧蓋膚(膚憲觸鑰製膚繭顧鏇繭) = 獵襯夢憲醖膚膚鏇蓋觸 築餘膚夢願餘蓋鏇蓋憲 (鬱網糧觸遞構範願選築 ) | ||||||
临床2期 | 6 | 鑰顧構鏇鬱襯範鹹衊衊(膚簾獵窪簾選選築鏇蓋) = 範夢廠膚膚淵齋鏇積淵 構夢網衊餘選鹹窪膚簾 (築繭製簾繭醖鹹構齋網, 0.2377) 更多 | - | 2022-03-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用